1,804 results match your criteria Nonseminomatous Testicular Tumors


Serum tumor markers and testicular germ cell tumors: a primer for radiologists.

Abdom Radiol (NY) 2018 Dec 11. Epub 2018 Dec 11.

University Hospitals Cleveland Medical Center, 11100 Euclid Ave, Cleveland, OH, 44106, USA.

Serum tumor markers (STMs) play a critical role in the diagnosis, staging and follow-up of both seminomatous and nonseminomatous testicular germ cell neoplasms. Levels of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH), especially those measured after orchiectomy, also have implications for patient prognosis. Given that testicular germ cell tumors represent the most common solid tumor in men aged 20-34, radiologists must have familiarity with the clinical utilization and implications of these STMs. Read More

View Article
December 2018
1 Read

Choriocarcinoma Syndrome as an Initial Presentation of Testicular Cancer.

Case Rep Oncol Med 2018 8;2018:8065615. Epub 2018 Nov 8.

Centro Universitario Contra el Cáncer, University Hospital "Dr. José Eleuterio González" and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.

Choriocarcinoma syndrome (CS) is a rare clinical entity within the spectrum of nonseminomatous germ-cell tumors (NSGCT). It is characterized by the abrupt establishment of rapidly progressive and hemorrhagic tumors associated with very high levels of the beta fraction of human chorionic gonadotropin (-hCG) and with a very poor prognosis, particularly in patients with -hCG values above 50,000 IU/L. We present the case of a 17-year-old man with a sudden onset nonmassive hemoptysis. Read More

View Article
November 2018

Staged surgical treatment of a primary duodenocaval fistula in a patient with metastatic nonseminomatous germ cell tumor.

J Vasc Surg Venous Lymphat Disord 2018 Oct 24. Epub 2018 Oct 24.

Division of Vascular Surgery, CHU de Québec, Quebec City, Quebec, Canada.

Endovascular exclusion of aortoenteric fistula has been described as a bridge to definitive open repair surgery. However, little is known about transposing this technique to treat duodenocaval fistula. We report a case of a 20-year-old man who presented with a duodenocaval fistula arising from a metastatic nonseminomatous germ cell tumor. Read More

View Article
October 2018

Diagnosis and management of the growing teratoma syndrome: A single-center experience and review of the literature.

Urol Oncol 2018 Dec 13;36(12):529.e23-529.e30. Epub 2018 Nov 13.

Department of Urology, University Hospital Cologne, Cologne, Germany. Electronic address:

Objectives: To evaluate the diagnostic, surgical as well as oncological outcome of patients with a growing teratoma syndrome.

Material And Methods: We performed a retrospective analysis including 680 patients with advanced nonseminomatous germ cell tumors who underwent a postchemotherapy retroperitoneal lymph node dissection. The peri- and postoperative outcome of 22 patients (3%) that fulfilled the criteria of a growing teratoma syndrome were analyzed: nonseminomatous germ cell tumors with increasing tumor size during or after chemotherapy despite normalized or decreasing tumor markers. Read More

View Article
December 2018
8 Reads

DNA methylation profiling as a tool for testicular germ cell tumors subtyping.

Epigenomics 2018 Nov 12. Epub 2018 Nov 12.

Cancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.

Aim: Assess differential patterns of selected five genes' promoter methylation among testicular germ cell tumors (TGCT) subtypes.

Materials & Methods:  CRIPTO, HOXA9, MGMT, RASSF1A and SCGB3A1 promoter methylation levels were evaluated by quantitative methylation-specific PCR in 161 TGCT and 16 controls. Associations between clinicopathological parameters and promoter methylation levels were assessed, and receiver operating characteristics curve analysis was performed. Read More

View Article
November 2018
12 Reads

Sentinel Node Biopsy in Clinical Stage I Testicular Cancer Enables Early Detection of Occult Metastatic Disease.

BJU Int 2018 Nov 11. Epub 2018 Nov 11.

Department of Oncological Urology, UMC Utrecht Cancer Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Objectives: To report the long-term results of the sentinel node approach in clinical stage I testicular tumour patients in our facility.

Patients And Methods: Analysis of 27 consecutive patients suspected of clinical stage I testicular germ cell tumour and treated with a sentinel node procedure at our tertiary referral centre. Sentinel nodes were identified using lymphoscintigraphy with or without single photo emission computed tomography with computed tomography. Read More

View Article
November 2018
5 Reads

Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study.

BMC Urol 2018 Oct 26;18(1):95. Epub 2018 Oct 26.

MVZ Hanse Histologikum, Hamburg, Germany.

Background: Primary retroperitoneal lymph node dissection (RPLND) ultimately lost its role as the standard management of clinical stage (CS) 1 nonseminomatous (NS) testicular germ cell tumours (GCTs) in Europe when the European Germ Cell Cancer Consensus Group released their recommendations in 2008. Current guide-lines recommend surgery only for selected patients but reasons for selection remain rather ill-defined. We evaluated the practice patterns of the management of CS1 patients and looked specifically to the role of RPLND among other standard treatment options. Read More

View Article
October 2018
7 Reads

N-cadherin expression in primary and metastatic testicular germ cell tumors.

J BUON 2018 Jul-Aug;23(4):1125-1129

Department of Surgical Pathology, Uludag University School of Medicine, Bursa, Turkey.

Purpose: Upregulation of N-cadherin in epithelial tumor cells has been reported to enhance the invasive process. Although the distribution of N-cadherin in the normal testis was demonstrated, there is no adequate information regarding its presence in testicular germ cell tumors (GCTs). Our purpose was to examine the expression and localization of N-cadherin in germ cell tumors of the testis and share our experience. Read More

View Article
October 2018
2 Reads

Huge right ventricular mass revealing a testicular nonseminomatous germ cell tumor.

J Saudi Heart Assoc 2019 Jan 18;31(1). Epub 2018 Aug 18.

Department of Paediatrics, Al-Kindy College of Medicine, University of Baghdad, Baghdad, IraqIraq.

View Article
January 2019
1 Read

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry.

J Clin Oncol 2018 Oct 4:JCO1800210. Epub 2018 Oct 4.

Richard Cathomas, Kantonsspital Graubünden, Chur; Dirk Klingbiel, Swiss Group for Clinical Cancer Research Coordinating Center; Silke Gillessen, University of Bern; Jörg Beyer, Inselspital, Bern University Hospital, University of Bern, Bern; Christian Fankhauser, University of Zürich, Zürich; Silke Gillessen, Kantonsspital St Gallen, St Gallen, Switzerland; Brandon Bernard, Dana-Farber Cancer Institute, Boston, MA; Anja Lorch, University of Düsseldorf, Düsseldorf; Christoph Oing, University Medical Center Hamburg-Eppendorf, Hamburg; Marcus Hentrich, Rotkreuzklinikum München, München, Germany; Xavier Garcia del Muro, Institute Catalan of Oncology, Bellvitge Biomedical Research Institute, University of Barcelona, Barcelona, Spain; Franco Morelli, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo; Ugo De Giorgi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Meldola, Italy; Mikhail Fedyanin, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia; and Hege Sagstuen Haugnes, University Hospital of North Norway and Universitetet i Tromsø-The Arctic University, Tromsø, Norway.

Purpose: Residual lesions after chemotherapy are frequent in metastatic seminoma. Watchful waiting is recommended for lesions < 3 cm as well as for fluorodeoxyglucose (FDG) positron emission tomography (PET)-negative lesions ≥ 3 cm. Information on the optimal management of PET-positive residual lesions ≥ 3 cm is lacking. Read More

View Article
October 2018
1 Read

Nodule Size After Chemotherapy and Primary-Tumor Teratoma Components Predict Malignancy of Residual Pulmonary Nodules in Metastatic Nonseminomatous Germ Cell Tumor.

Ann Surg Oncol 2018 Nov 6;25(12):3668-3675. Epub 2018 Sep 6.

Urology Division, National Cancer Center Hospital, Tokyo, Japan.

Background: The treatment goal for visceral metastatic nonseminomatous germ cell tumor (NSGCT) is to remove any residual teratoma or viable NSGCT after chemotherapy. However, this provides no therapeutic benefit to patients whose metastases necrotize on their own. This study therefore analyzed NSGCTs with pulmonary metastases to determine preoperative factors that predict necrosis and could help identify patients who might be treated with monitoring rather than surgery. Read More

View Article
November 2018

Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later.

Urology 2018 Aug 28. Epub 2018 Aug 28.

Section of Urology, Department of Surgery, University of Chicago, Chicago, IL.

View Article
August 2018
3 Reads

Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.

Eur Urol Focus 2018 Jul 16. Epub 2018 Jul 16.

Upstate Medical University, Syracuse, NY, USA; Foundation Medicine Inc., Cambridge, MA, USA.

Background: Although both seminomatous and nonseminomatous testicular germ cell tumors (TGCTs) have favorable outcomes with chemotherapy, a subset is chemorefractory, and novel therapeutic options are needed.

Objective: To molecularly characterize chemotherapy-refractory TGCTs.

Design, Setting, And Participants: Archival tissues from 107 chemotherapy-treated and relapsed TGCT patients (23 seminomas; 84 nonseminomas) underwent hybrid-capture-based genomic profiling to evaluate four classes of genomic alterations (GAs). Read More

View Article
July 2018
2 Reads

Huge right ventricular mass revealing a testicular nonseminomatous germ cell tumor.

J Saudi Heart Assoc 2018 Jul 24;30(3):279-283. Epub 2018 Feb 24.

Department of Cardiology, Mohammed VI University Hospital Center, BP 4806 Oujda University, 60049 Oujda, Morocco.

Background: Cardiac intracavitary metastases from a testicular cancer are very unusual, and intra-cardiac metastasis is exceptionally the first expression of a noncardiac primary neoplasm. We report a case of a young patient for whom a cardiac symptom led to the diagnosis of a metastatic testicular cancer.

Case Presentation: Our presentation describes an unusual case of a 32 years-old male patient admitted for dyspnea, in whom full examination and tests led to the diagnosis of a huge right ventricular mass revealing a testicular malignant teratoma. Read More

View Article
July 2018
10 Reads

Prognostic markers in clinical stage I seminoma and nonseminomatous germ cell tumours.

Curr Opin Urol 2018 Sep;28(5):448-453

Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, Ohio, USA.

Purpose Of Review: Testicular germ cell tumour (TGCT) is a common malignancy among young men. There is controversy regarding the best approach for patients with clinical stage I disease due to rates of relapse with active surveillance in contrast to overtreatment with adjuvant therapy. The aim of this review is to describe the role of prognostic factors in this setting. Read More

View Article
September 2018
1 Read

Dose-reduced first cycle of chemotherapy for prevention of life-threatening acute complications in nonseminomatous germ cell tumor patients with ultra high tumor markers and/or poor performance status.

J Cancer Res Clin Oncol 2018 Sep 5;144(9):1817-1823. Epub 2018 Jul 5.

Department of Clinical Pharmacology and Chemotherapy, N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, 115478, Russia.

Purpose: Patients with metastatic nonseminomatous germ cell tumors (mNSGCT) and a high tumor burden or a poor performance status at initial diagnosis are at risk from potentially life-threatening early complications during or after the first chemotherapy cycle. The outcomes with dose-reduced first cycle of chemotherapy in this population of patients are not well established.

Methods: We performed a retrospective analysis of patients with mNSGCT and International Germ Cell Cancer Collaborative Group (IGCCCG) poor risk features. Read More

View Article
September 2018
23 Reads

Hematologic Malignancies Associated With Mediastinal Germ Cell Tumors: 10 Years' Experience at Thailand's National Pediatric Tertiary Referral Center.

J Pediatr Hematol Oncol 2018 Aug;40(6):450-455

Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok.

Mediastinal germ cell tumor (MGCT), which accounts for 1% to 3% of extragonadal germ cell tumors, has unique manifestations; it is associated with several types of hematologic malignancy, particularly myeloid neoplasm. The aim of this study was to report the 10-year incidence, clinical characteristics, and outcomes of MGCT at Thailand's national pediatric tertiary referral center. This retrospective study included patients diagnosed with MGCT at the Department of Pediatrics, Siriraj Hospital during 2005 to 2014. Read More

View Article
August 2018
10 Reads

A Review of Outcomes and Technique for the Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer.

Adv Urol 2018 3;2018:2146080. Epub 2018 May 3.

Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Objectives: The robotic-assisted laparoscopic retroperitoneal lymph node dissection (R-RPLND) represents a new frontier in the surgical management of testicular cancer in the realm of minimally invasive urologic oncology. We aimed to review the early outcomes as compared to the laparoscopic and open approaches as well as describe the operative technique for the R-RPLND.

Materials And Methods: We reviewed all the literature related to the R-RPLND based on an electronic PubMed search up until July 2017. Read More

View Article
May 2018
4 Reads

The Use of Modified Templates in Early and Advanced Stage Nonseminomatous Germ Cell Tumor.

Adv Urol 2018 5;2018:6783147. Epub 2018 Apr 5.

Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

The surgical management of both early and advanced stage germ cell tumors of the testis remains a complex process of surgical decision making to maximize oncologic control while minimizing morbidity. Over the past 5 decades, the evolution of the surgical template for retroperitoneal lymphadenectomy (RPLND) has resulted in important modifications to achieve these goals. In this review, we will characterize the historical motivating factors that led to the modified template, outline patient and clinical factors in selecting these approaches in both early and advanced stage disease, and briefly discuss future horizons for their implementation. Read More

View Article
April 2018
2 Reads

Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP.

Adv Urol 2018 2;2018:8781698. Epub 2018 Apr 2.

Institute of Cancer Research and Royal Marsden Hospital FT, Sutton, Surrey, UK.

Testicular germ cell tumours are the commonest tumours of young men and are broadly managed either as pure seminomas or as 'nonseminomas'. The management of Stage 1 nonseminomatous germ cell tumours (NSGCTs), beyond surgical removal of the primary tumour at orchidectomy, is somewhat controversial. Cancer-specific survival rates in these patients are in the order of 99% regardless of whether surveillance, retroperitoneal lymph node dissection, or adjuvant chemotherapy is employed. Read More

View Article
April 2018
5 Reads

Minimally Invasive Retroperitoneal Lymphadenectomy.

J Endourol 2018 May;32(S1):S97-S104

Department of Urology, Paracelsus Medical University , Salzburg, Austria .

The feasibility of laparoscopic retroperitoneal lymphadenectomy (RLA) for testicular cancer was shown >25 years ago. Initially the indication was clinical stage I (CS I) nonseminomatous germ cell tumor (NSGCT). Compared with that of open surgery, the morbidity was much decreased. Read More

View Article
May 2018
1 Read

Decision analysis defining optimal management of clinical stage 1 high-risk nonseminomatous germ cell testicular cancer with lymphovascular invasion.

Urol Oncol 2018 Jul 10;36(7):342.e1-342.e6. Epub 2018 May 10.

Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN.

Background: Risk of recurrent disease for men with clinical stage 1 high-risk nonseminomatous germ cell testicular cancer (CS1 NSGCT) with lymphovascular invasion (LVI) after orchiectomy is 50% and current treatment options (surveillance [S], retroperitoneal lymph node dissection [RPLND], or 1 cycle of BEP [BEP ×1]) are associated with a 99% disease specific survival, therefore practice patterns vary. We performed a decision analysis using updated data of long-term complications for men with CS1 NSGCT with LVI to quantify and assess relative treatment values.

Methods: Decision analysis included previously defined utilities (via standard gamble) for posttreatment states of living from 0 (death from disease) to 1 (alive in perfect health) and updated morbidity probabilities. Read More

View Article
July 2018
3 Reads

Histopathological pattern of testicular diseases in western Saudi Arabia.

Saudi Med J 2018 May;39(5):476-480

Department of Pathology, Taibah University, Madinah, Kingdom of Saudi Arabia. E-mail.

Objectives: To determine the histopathological pattern of testicular diseases among Saudi patients in Madinah, Saudi Arabia.

Methods: This retrospective histopathology-based study was conducted in a tertiary care hospital in Madinah, Saudi Arabia, from January 2006 to December 2017. The data collected were entered into MS-Excel and  analyzed using the Statistical Packages for Social Sciences Version 19. Read More

View Article
May 2018
2 Reads

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.

Urology 2018 Aug 25;118:114-118. Epub 2018 Apr 25.

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Objective: To evaluate the oncologic outcomes and histologic concordance of postchemotherapy residual liver mass resection with postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).

Methods: Retrospective review of our prospectively maintained germ cell tumor (GCT) surgical database identified patients with nonseminomatous GCT who underwent both postchemotherapy residual liver mass resection and PC-RPLND between 1990 and 2015.

Results: A total of 36 patients were identified, of whom 29 (81%) presented with a liver mass at initial diagnosis and 17 (47%) received second-line chemotherapy before liver resection. Read More

View Article
August 2018
2 Reads

Outcomes of active surveillance of clinical stage I non-seminomatous germ cell tumors: sub-analysis of the multi-institutional nationwide case series of the Japanese Urological Association.

Jpn J Clin Oncol 2018 Jun;48(6):565-569

Urology Division, National Cancer Center Hospital, Tokyo, Japan.

Objective: To evaluate the survival rate and risk factors of distant metastasis in stage I non-seminomatous germ cell tumor (NSGCT) cases without adjuvant treatments.

Methods: A national testicular cancer survey of cases newly diagnosed in 2005 and 2008 was conducted by the Japanese Urological Association in 2011. In 159 stage I NSGCT cases, 132 were followed by active surveillance after high orchiectomy. Read More

View Article
June 2018
3 Reads

Adolescent and Young Adult Testicular Germ Cell Tumors: Special Considerations.

Adv Urol 2018 31;2018:2375176. Epub 2018 Jan 31.

Department of Surgery, Division of Urology, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.

While testicular germ cell tumors (T-GCTs) make up only 0.5% of pediatric malignancies and less than 2% of adult malignancies, they comprise 14% of adolescent malignancies, making it the most common solid tumor in this age group. The transition in incidence at this age is also accompanied by a transition in tumor histology with adolescents having mostly pure embryonal carcinoma and mixed nonseminomatous germ cell tumors. Read More

View Article
January 2018
5 Reads

Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent.

Clin Cancer Res 2018 Aug 4;24(15):3755-3766. Epub 2018 Apr 4.

Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), Oncobell Program, L'Hospitalet del Llobregat, Barcelona, Catalonia, Spain.

To investigate the genetic basis of cisplatin resistance as efficacy of cisplatin-based chemotherapy in the treatment of distinct malignancies is often hampered by intrinsic or acquired drug resistance of tumor cells. We produced 14 orthoxenograft transplanting human nonseminomatous testicular germ cell tumors (TGCT) in mice, keeping the primary tumor features in terms of genotype, phenotype, and sensitivity to cisplatin. Chromosomal and genetic alterations were evaluated in matched cisplatin-sensitive and their counterpart orthoxenografts that developed resistance to cisplatin in nude mice. Read More

View Article
August 2018
17 Reads
8.720 Impact Factor

Rare Metastatic Testicular Cancer in a Veteran.

Curr Urol 2018 Feb 30;11(2):110-112. Epub 2017 Dec 30.

Department of Michael E. DeBakey VA Medical Center & Baylor College of Medicine, Houston, TX, USA.

Testicular yolk sac tumor (YST) is a nonseminomatous germ cell tumor that predominantly affects prepubescent boys. Pure endometrioid variant YST is rare, with only 1 report in the literature. We present the first reported case of en-dometrioid variant YST with mature teratoma in the retro-peritoneal specimen. Read More

View Article
February 2018
1 Read

Bilateral Testicular Germ Cell Tumors: A Case-Series From a UK-Based Tertiary Referral Center Over 19 Years.

Clin Genitourin Cancer 2018 06 2;16(3):e513-e516. Epub 2018 Mar 2.

Department of Medical Oncology, Oxford Cancer Centre, Churchill Hospital, Oxford, United Kingdom. Electronic address:

View Article
June 2018
4 Reads

Managing seminomatous and nonseminomatous germ cell tumors.

Curr Opin Oncol 2018 05;30(3):181-188

Department of Genitourinary Medical Oncology.

Purpose Of Review: In the present review, we summarize the recent developments in the management of germ cell tumors (GCTs).

Recent Findings: Treatment-related acute and late-onset toxicity remains a key challenge in the management of GCTs, with recent evidence showing that the adverse health outcomes of etoposide and cisplatin for four cycles in comparison to bleomycin, etoposide, and cisplatin for three cycles appear to be similar. Recent data showed that multidisciplinary clinic approach and management in experienced academic centers were associated with improved overall survival in GCT patients. Read More

View Article
May 2018
1 Read

Pericardial effusion as an atypical initial presentation of extra-gonadal nonseminomatous germ cell tumor: a case report and literature review.

Oxf Med Case Reports 2018 Feb 22;2018(2):omx097. Epub 2018 Feb 22.

Division of Hematology and Oncology, Department of Internal Medicine, University of FloridaCollege of Medicine, Gainesville, FL, USA.

Extra gonadal germ cell tumors have variable clinical presentations and locations. We report a case of an extra-gonadal germ cell tumor in a 26-year-old male who presented with chest pain. Imaging revealed a large pericardial effusion with underlying mass invading the pericardium. Read More

View Article
February 2018

Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma.

Adv Urol 2018 1;2018:7978958. Epub 2018 Feb 1.

University of Southern California Institute of Urology, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.

Reducing the long-term morbidity in testicular cancer survivors represents a major area of interest. External beam radiation therapy and systemic chemotherapy are established treatments for seminoma; however, they are associated with late toxicities such as cardiovascular disease, insulin resistance, and secondary malignancy. Retroperitoneal lymph node dissection (RPLND) is a standard treatment for nonseminomatous germ cell tumors (NSGCT) that has minimal long-term morbidity. Read More

View Article
February 2018
6 Reads

EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.

Mol Cancer Ther 2018 May 26;17(5):1079-1089. Epub 2018 Feb 26.

Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.

Germ cell tumors (GCT) are malignant tumors that arise from pluripotent embryonic germ cells and occur in children and young adults. GCTs are treated with cisplatin-based regimens which, while overall effective, fail to cure all patients and cause significant adverse late effects. The seminoma and nonseminoma forms of GCT exhibit distinct differentiation states, clinical behavior, and response to treatment; however, the molecular mechanisms of GCT differentiation are not fully understood. Read More

View Article
May 2018
9 Reads

Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.

J Urol 2018 Jul 21;200(1):126-135. Epub 2018 Feb 21.

Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Electronic address:

Purpose: Retroperitoneal lymph node dissection is recommended for residual masses greater than 1 cm after chemotherapy of nonseminomatous germ cell tumors. Currently there is no reliable predictor of post-chemotherapy retroperitoneal lymph node dissection histology. Up to 50% of patients harbor necrosis/fibrosis only so that a potentially morbid surgery has limited therapeutic value. Read More

View Article
July 2018
55 Reads

A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.

Eur Urol Focus 2018 Feb 7. Epub 2018 Feb 7.

Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. Electronic address:

Background: Postchemotherapy retroperitoneal lymph node dissection (pcRPLND) is indicated in testicular cancer patients with normalised or plateaued serum tumour markers and residual retroperitoneal lesions >1cm. Challenges remain in predicting postchemotherapy residual mass (pcRM) histology, which may lead to unnecessary surgery.

Objective: To develop an accurate model to predict pcRM histology in patients with nonseminomatous germ cell tumours (NSGCTs). Read More

View Article
February 2018
6 Reads

Onco-testicular sperm extraction (Onco-TESE) from a single testis with metachronous bilateral testicular cancer: a case report.

Basic Clin Androl 2018 25;28. Epub 2018 Jan 25.

1Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 036-8562 Japan.

Background: Although oncologic testicular sperm extraction (onco-TESE) has been increasingly practiced, the evidence of onco-TESE performed in patients with testicular cancer is insufficient. Furthermore, in bilateral testicular cancer, accounting for 0.5%-1% of testicular cancers, onco-TESE is more challenging and has been insufficiently reported. Read More

View Article
January 2018
20 Reads

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.

Urology 2018 Apr 2;114:133-138. Epub 2018 Feb 2.

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY. Electronic address:

Objective: To determine the pathologic findings and clinical outcome of patients with pure embryonal carcinoma (EC) of the testis who were diagnosed with testis cancer from January 1989 to January 2013 who underwent an orchiectomy, cisplatin-based chemotherapy and a postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).

Methods: We compared those patients with 100% EC with those with mixed nonseminomatous germ cell tumor pathology who underwent a PC-RPLND.

Results: Of 1105 patients who underwent a PC-RPLND, 145 had pure EC. Read More

View Article
April 2018
10 Reads

Late relapse in stage I of nonseminomatous germ cell testicular cancer on surveillance.

Bratisl Lek Listy 2018 ;119(1):3-5

Objective: Primary aim was to assess relapse‑free survival (RFS) in patients with clinical stage I (CS I) of non-seminomatous germ cell testicular tumors (NSGCTT) undergoing surveillance after orchiectomy. The secondary aim was to examine differences in risk factors in patients with early relapse (ER 2 years) and very late relapse (VLR > 5 years).

Methods: Cross-sectional study analyzed 25‑year single‑center experiences with 198 CS I NSGCTT patients according the time to relapse. Read More

View Article
June 2018
3 Reads

Placental Site Trophoblastic Tumor in Nonseminomatous Mixed Germ Cell Tumors of the Testis: a Case Report and Review of the Literature.

Clin Genitourin Cancer 2018 04 27;16(2):e349-e354. Epub 2017 Dec 27.

Service de Pathologie, Hôpital Saint-Louis, AP-HP, Paris, France; Service de Recherches en Hémato-immunologie, CEA, Hôpital Saint-Louis, Paris, France; Université Paris Diderot, UMR E_5, Institut Universitaire d'Hématologie, Paris, France; Université Paris Diderot, Inserm, UMR_S1165, Institut Universitaire d'Hématologie, Paris, France. Electronic address:

View Article

Hepatic angiosarcomatous transformation of a mediastinal germinal cell tumor: A care case report.

Medicine (Baltimore) 2017 Dec;96(51):e9152

Department of Radiology, Memorial Sloan Kettering Cancer Center, York Avenue, New York, NY, USA.

Rationale: Mediastinal nonseminomatous germ cell tumor (NSGCT) is an uncommon entity. Metastatic hepatic sarcomatous transformation is rare.

Patient Concerns: We report a 24-year-old man with no previous related medical history presented with chest pain and left arm numbness. Read More

View Article
December 2017
5 Reads

Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.

Med Oncol 2018 Jan 31;35(3):21. Epub 2018 Jan 31.

Department of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.

The frequency of co-occurrence between germ cell tumor (GCT) components in non-seminomatous germ cell tumor (NSGCT) orchiectomy specimens and their correlation with histologic findings in subsequent retroperitoneal lymph node dissection (RPLND) specimens have not been well characterized. The objective of the study was to report the first detailed clinicopathologic analysis of NSGCT orchiectomy and RPLND samples to determine the likelihood and agreement of the co-occurrence of GCT components. A total of 118 consecutive patients with NSGCT treated between 1988 and 2012 who underwent both orchiectomy and RPLND at a single academic tertiary care center were analyzed. Read More

View Article
January 2018
10 Reads

Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients.

Bone Marrow Transplant 2018 Jul 24;53(7):820-825. Epub 2018 Jan 24.

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Sequential high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is a curative option in relapsing germ cell tumor (GCT) patients, and complete remission (CR) after the first ASCT (early CR2) is associated with favorable outcome. Prognostic factors predicting early CR2 have not been investigated so far. We analyzed consecutive patients with a first relapse of GCT treated with three sequential cycles of carboplatin/etoposide-based HDCT with ASCT in the two largest academic centers in Switzerland. Read More

View Article
July 2018
5 Reads

Germ cell tumor causing pleural effusion: A diagnostic dilemma.

Indian J Tuberc 2018 Jan 24;65(1):80-83. Epub 2017 Aug 24.

Professor, Department of Pulmonary Medicine, Government Medical College and Hospital, Sector 32 A, Chandigarh 160030, India.

Straw colored pleural fluid with raised adenosine deaminase (ADA) levels in young healthy adults usually raises suspicion of tuberculosis, sometimes leading to laxity in carrying thorough physical examination and missing out some important clues with potential disastrous consequences. A 35-year-old male was diagnosed to have left pleural effusion and anti-tubercular treatment was started on the basis of straw colored, lymphocyte-predominant pleural fluid with significantly raised ADA levels. When there was no improvement after 1 month of treatment he was investigated further and found to have a mediastinal mass along with hydro-pneumothorax. Read More

View Article
January 2018
20 Reads

The Significance of Spermatic Cord Involvement by Testicular Germ Cell Tumors: Should We Be Staging Discontinuous Invasion From Involved Lymphovascular Spaces Differently From Direct Extension?

Am J Surg Pathol 2018 Mar;42(3):306-311

Departments of Pathology and Laboratory Medicine.

The recent 8th edition of the American Joint Committee on Cancer (AJCC) staging manual had multiple changes concerning how pathologists should stage germ cell tumors (GCTs) of the testis. A significant one concerns the impact of different types of spermatic cord involvement, specifically direct tumor extension versus discontinuous involvement by invasion through lymphovascular spaces. We compared clinicopathologic findings and outcome data between 2 cohorts with these findings to evaluate the validity of the change in the AJCC 8th edition manual. Read More

View Article
March 2018
19 Reads

Recurrent Masses after Testicular Cancer: Growing Teratoma Syndrome. A Case Report and Review of the Literature.

Case Rep Oncol 2017 Sep-Dec;10(3):910-915. Epub 2017 Oct 17.

Department of Oncology, CHU UcL Namur, Yvoir, Belgium.

Background: Growing teratoma syndrome is a rare syndrome that affects patients with nonseminomatous germ-cell tumors (NSGCTs). It is characterized by recurrent growing masses that appear during or after chemotherapy in the presence of normal levels of tumor markers. Histological examination is the only way to confirm the diagnosis. Read More

View Article
October 2017
12 Reads

Extraperitoneal robot-assisted laparoscopic retroperitoneal lymph node dissection for early-stage testicular nonseminomatous germ cell tumors: A case report and literature review.

Medicine (Baltimore) 2017 Dec;96(49):e8938

Department of Urology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.

Rationale: Typically robot-assisted laparoscopic retroperitoneal lymph node dissection (R-RPLND) has been performed via a transperitoneal approach. Herein we report the first case of a novel R-RPLND using an extraperitoneal approach.

Patient Concerns: A 38-year-old man presented with an enlarging right scrotal mass. Read More

View Article
December 2017
25 Reads

Outcome of Critically Ill Patients with Testicular Cancer.

Biomed Res Int 2017 26;2017:3702605. Epub 2017 Oct 26.

Department of Critical Care Medicine, Instituto Nacional de Cancerología, 14080 Mexico City, Mexico.

Purpose: To evaluate the clinical characteristics and outcomes of critically ill patients with testicular cancer (TC) admitted to an oncological intensive care unit (ICU).

Methods: This was a prospective observational study. There were no interventions. Read More

View Article
July 2018
24 Reads

IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.

J Pathol 2018 Feb 10;244(2):242-253. Epub 2018 Jan 10.

Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, Institute of Cancer Research, London, UK.

Testicular germ cell tumours (TGCTs) are the most frequent malignancy and cause of death from solid tumours in the 20- to 40-year age group. Although most cases show sensitivity to cis-platinum-based chemotherapy, this is associated with long-term toxicities and chemo-resistance. Roles for receptor tyrosine kinases other than KIT are largely unknown in TGCT. Read More

View Article
February 2018
13 Reads